RGEVX | RGVAX | RGEVX / RGVAX | |
Total Expense Ratio | 1.05 | 1.33 | 79% |
Annual Report Gross Expense Ratio | 1.09 | 1.37 | 80% |
Fund Existence | 11 years | 23 years | - |
Gain YTD | 7.141 | 6.847 | 104% |
Front Load | N/A | N/A | - |
Min. Initial Investment | 250 | 250 | 100% |
Min. Initial Investment IRA | N/A | N/A | - |
Net Assets | 23.8B | 23.8B | 100% |
Annual Yield % from dividends | 3.60 | 3.33 | 108% |
Returns for 1 year | 4.93 | 4.64 | 106% |
Returns for 3 years | 12.50 | 11.50 | 109% |
Returns for 5 years | -7.31 | -8.56 | 85% |
Returns for 10 years | 2.19 | -0.83 | -263% |
1 Day | |||
---|---|---|---|
ETFs / NAME | Price $ | Chg $ | Chg % |
KLXY | 26.61 | 0.35 | +1.33% |
KraneShares Global Luxury Index ETF | |||
FUND | 8.39 | 0.03 | +0.36% |
Sprott Focus Trust | |||
DABS | 51.20 | 0.18 | +0.35% |
Doubleline Asset-Backed Securities ETF | |||
JSI | 52.32 | 0.02 | +0.04% |
Janus Henderson Securitized Income ETF | |||
BIB | 66.21 | -0.46 | -0.69% |
ProShares Ultra Nasdaq Biotechnology |